Evercyte - the pharmacocellomicsTM company.

Vision
Acceleration of drug finding and development by reduction of development time and cost by introducing panels of immortalized human cell strains for drug screening strategies.

Evercyte will establish the new concept of “pharmacocellomicsTM” in the field of pre-clinical developments.
Therefore, we will provide primary cells from different patients and tissues that are immortalized by telomerase or other strategies (SV40; SNEV) that we have established. Thus we guarantee cell strains with the most similar phenotype to the primary cells in sufficient amounts to perform reproducible preclinical drug testing. We will deliver (i) single immortalized cell strains including mesenchymal stem cells that can be differentiated to the cell type of interest; (ii) cell panels including sufficient cell strains of different tissues and/or donors of different status (healthy, diseased, young, old, etc) in order to generate statistically meaningful data that allow to estimate drug efficiencies and toxicity with high predictive power. Finally, (iii) we will establish customer-tailored immortalized cell strains according to the needs of specific customers.

Biotechnology

Life Sciences

Pharmaceutical

Evercyte GmbH

Evercyte GmbH's headquarters in Wien, Austria

Otto Kanzler

Regina Grillari

This department provides strategic direction and oversight for the entire organization.

Executive Leadership

This department conducts research and provides expert advice in scientific fields to drive innovation and development.

Evercyte GmbH

Org chart

Teams

Executive Leadership

Scientific Research

Offices

Evercyte GmbH

Org chart

Teams

Executive Leadership

Scientific Research

Offices

Related companies